Department of Biology, Faculty of Sciences, University of Zanjan, Zanjan, Iran.
Department of Biology, Faculty of Sciences, University of Zanjan, Zanjan, Iran.
Enzyme Microb Technol. 2017 Dec;107:64-71. doi: 10.1016/j.enzmictec.2017.08.006. Epub 2017 Aug 24.
Chondroitin Sulfate Proteoglycans (CSPGs) are the main inhibitors for axon regeneration after damaging of Central Nervous System (CNS). Chondroitinase ABC I (cABC I) can degrade CSPGs by removing chondroitin and dermatan sulfate side chains from proteoglycans. Hence, it may be considered as an attractive candidate in biomedicine. For practical applications of this enzyme, increasing the effective circulating level and reducing the number and volume of injections for patients is one of the main concerns which is directly related to conformational stability and catalytic efficiency of the enzyme. Structural examination of C-terminal domain of cABC I reveals that there are a few numbers of residues in helical conformation which are positioned at the context of a cohesive structural organization of β-strands. In line with our previous studies on C-terminal domain of cABC I and regarding the residues in α-helix conformation; we designed and constructs some representative mutants including M889K, M889L, L679D/M889K and L679S/M889K. According to structural and functional characterization of protein variants and regarding the wide range of variability in determining parameters for β-sheet conformation, we proposed a model in which the structural integrity of β-strands at C-terminal domain can be manipulated and directed toward a new patterns of organization, some of them may have positive effects on the structural and functional features of the enzyme. Using this strategy it may be possible to improve functional and structural features of the enzyme by engineering the intra-molecular interactions in positions far from the active site of the enzyme.
硫酸软骨素蛋白聚糖(CSPGs)是中枢神经系统(CNS)损伤后轴突再生的主要抑制剂。软骨素酶 ABC I(cABC I)可以通过去除蛋白聚糖中的软骨素和硫酸皮肤素侧链来降解 CSPGs。因此,它可能被认为是生物医学中的一个有吸引力的候选物。为了将这种酶实际应用于临床,增加有效循环水平并减少患者的注射次数和剂量是主要关注点之一,这与酶的构象稳定性和催化效率直接相关。对 cABC I C 末端结构域的结构检查表明,在β-折叠的凝聚结构组织的背景下,存在少数处于螺旋构象的残基。根据我们之前对 cABC I C 末端结构域的研究,以及处于α-螺旋构象的残基;我们设计并构建了一些代表性的突变体,包括 M889K、M889L、L679D/M889K 和 L679S/M889K。根据蛋白变体的结构和功能特征,以及确定β-折叠构象参数的广泛可变性,我们提出了一个模型,其中 C 末端结构域的β-折叠结构的完整性可以被操纵,并指向新的组织模式,其中一些可能对酶的结构和功能特征产生积极影响。通过在远离酶活性位点的位置设计分子内相互作用,这种策略可能可以改善酶的功能和结构特征。